From: Assessment of a new point-of-care system for detection of prostate specific antigen
PSA < 4 Concile® | PSA ≥ 4 Concile® | PSA < 4 Concile® | PSA ≥ 4 Concile® | PSA < 4 Centaur® | PSA ≥ 4 Centaur® | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
PSA < 4 Centaur® | 129 | 13 | 142 (71.7 %) | PSA < 4 Immulite® | 127 | 4 | 131 (66.2 %) | PSA < 4 Immulite® | 131 | 0 | 131 (66.2 %) |
PSA ≥ 4 Centaur® | 0 | 56 | 56 (28.3 %) | PSA ≥ 4 Immulite® | 2 | 65 | 67 (33.8 %) | PSA ≥ 4 Immulite® | 11 | 56 | 67 (33.8 %) |
129 (65.2 %) | 69 (34.8 %) | 198 (100.0 %) | 129 (65.2 %) | 69 (34.8 %) | 198 (100.0 %) | 142 (71.7 %) | 56 (28.3 %) | 198 (100.0 %) |